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Exploiting macrophage autophagy-lysosomal
biogenesis as a therapy for atherosclerosis
Ismail Sergin1, Trent D. Evans1, Xiangyu Zhang1, Somashubhra Bhattacharya1, Carl J. Stokes1, Eric Song1, Sahl Ali1,
Babak Dehestani1, Karyn B. Holloway1, Paul S. Micevych1, Ali Javaheri1, Jan R. Crowley2, Andrea Ballabio3,
Joel D. Schilling1,4, Slava Epelman5, Conrad C. Weihl6, Abhinav Diwan1, Daping Fan7, Mohamed A. Zayed8
& Babak Razani1,4
Macrophages specialize in removing lipids and debris present in the atherosclerotic plaque.
However, plaque progression renders macrophages unable to degrade exogenous atherogenic
material and endogenous cargo including dysfunctional proteins and organelles. Here we
show that a decline in the autophagy–lysosome system contributes to this as evidenced by a
derangement in key autophagy markers in both mouse and human atherosclerotic plaques. By
augmenting macrophage TFEB, the master transcriptional regulator of autophagy–lysosomal
biogenesis, we can reverse the autophagy dysfunction of plaques, enhance aggrephagy of
p62-enriched protein aggregates and blunt macrophage apoptosis and pro-inﬂammatory
IL-1b levels, leading to reduced atherosclerosis. In order to harness this degradative response
therapeutically, we also describe a natural sugar called trehalose as an inducer of macrophage
autophagy–lysosomal biogenesis and show trehalose’s ability to recapitulate the
atheroprotective properties of macrophage TFEB overexpression. Our data support this
practical method of enhancing the degradative capacity of macrophages as a therapy for
atherosclerotic vascular disease.
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T
he macrophage is a central player in atherosclerotic
progression. Insidious macrophage inﬁltration of the
nascent plaque, phagocytosis of deposited lipid and cellular
debris, foam cell formation, and progressive macrophage
dysfunction and inﬂammatory signalling constitute some of the
major events during atherogenesis. Understanding the cellular
processes that underlie macrophage dysfunction remains an
important area of investigation both scientiﬁcally and clinically,
serving as the basis for future therapeutics. An area that
has garnered substantial recent focus is autophagy, a highly
evolutionarily conserved process with critical roles in the
degradation and recycling of long-lived/damaged intracellular
material including accumulated lipids1,2. We and others have
shown that disruption of macrophage autophagy in mice
(by deletion of the essential autophagy protein ATG5) leads to
marked increases in atherosclerosis3–5. Proposed mechanisms for
this observation include reductions in lipophagy and the delivery
of cholesteryl esters for lysosome-mediated cholesterol efﬂux,
hyperactivation of the inﬂammasome and IL-1b signalling, and
increased cell death from accumulation of cytotoxic protein
aggregates.
However, details regarding the autophagy dysfunction that
occurs in atherosclerotic macrophages, the triggers that result in
such dysfunction and whether stimulation of macrophage
autophagy can be atheroprotective remain unclear. Using the
accumulation of the autophagy marker p62/SQSTM1, a chaper-
one for selective autophagy of cargo such as protein aggregates,
we have previously demonstrated that macrophages develop a
progressive autophagy dysfunction in the developing plaque3,6.
Regarding the trigger for autophagy dysfunction, a critical factor
appears to be the functional status of macrophage lysosomes.
Since lysosomes mediate the overall degradative capacity of
cells including autophagosome processing, the development of
lipid-induced lysosomal dysfunction in plaque macrophages is an
important contributor to the observed autophagy deﬁciency7–12.
Thus, attempts at reducing atherosclerosis by correcting the
degradative capacity of macrophages would most likely succeed
by stimulating the autophagy–lysosome system as a whole.
Recent discovery of the transcription factor TFEB as the
predominant transcriptional activator of a broad network of
autophagy and lysosomal genes (that is, master regulator of
autophagy–lysosomal biogenesis) has enabled serious considera-
tion of this idea13,14. A member of the MiT/TFE helix–loop–helix
subfamily, TFEB, initiates an autophagy–lysosomal biogenesis
programme, thus stimulating the overall degradative capacity of
cells14,15. TFEB has also recently been demonstrated to increase
lysosomal lipid catabolism, lipolysis and cellular fatty-acid
oxidation16,17. This provides an exciting new way to reverse
macrophage dysfunction by enhancing autophagy–lysosomal
function. By overexpressing TFEB in cultured macrophages, we
recently showed the ability of autophagy–lysosomal biogenesis
to reverse the autophagy–lysosomal dysfunction instigated by
atherogenic lipids and to have several functional beneﬁts such as
induction of cholesterol efﬂux, dampening of inﬂammasome acti-
vation and clearance of polyubiquitinated protein aggregates12. It
remains unclear how autophagy–lysosome dysfunction manifests
and progresses in atherosclerotic plaques, and whether enhancing
macrophage autophagy–lysosomal biogenesis can be effective
against atherosclerosis.
A second crucial question is whether the macrophage
autophagy–lysosomal degradation system can be stimulated
via pharmacological means to confer atheroprotection. Trehalose
is a non-reducing natural disaccharide (a,a-1,1-glucoside)
synthesized endogenously by non-mammalian organisms such
as insects, crustaceans and certain plants18. Present in high
concentration in these organisms, trehalose is thought to provide
protection against environmental stresses such as osmotic and
temperature shocks by stabilizing biomolecules18,19. In fact, the
pharmaceutical industry uses trehalose as a stabilizer excipient in
numerous medicines. In the nutraceutical industry, trehalose has
even been used as a sweetener because of its mild sweetness as
compared to its other closely related non-reducing disaccharide
sucrose20,21. Interestingly, there is a sizable body of literature
demonstrating trehalose’s ability to induce autophagy, although
the mechanism remains unknown22–29. This property has been
exploited by several studies in the neurodegeneration ﬁeld to
reduce aggregate formation in mouse models of Huntington’s,
Parkinson’s and Lou Gehrig’s (amyotrophic lateral sclerosis)
disease22,24,26. Owing to trehalose’s ability to induce autophagy
and ameliorate various protein aggregation neurodegenerative
diseases and our ﬁnding of TFEB as an autophagy inducer parti-
cularly of protein aggregates, we became interested in evaluating
the effects of trehalose in the induction of macrophage TFEB,
autophagy–lysosomal biogenesis and atherosclerosis.
In the ﬁrst part of this manuscript, we characterize the
progressive macrophage autophagy–lysosomal dysfunction that
occurs in both murine and human atherosclerotic plaques
and mechanistically explore how macrophage-speciﬁc TFEB
overexpression can rescue these defects to reduce atherosclerotic
plaques. In the second part of this manuscript, we leverage
the prodegradative response of macrophages for therapeutic
purposes by describing trehalose as a viable and practical method
of stimulating autophagy–lysosomal biogenesis to reduce
atherosclerosis.
Results
Atherosclerotic plaques develop autophagy dysfunction. Although
the link between deﬁcient macrophage autophagy and increased
atherosclerosis has been reported by several groups, including
ours3–6, the exact nature of the autophagy dysfunction that takes
place in atherosclerotic macrophages is unclear. Macrophages of
the atherosclerotic plaque are known to be the predominant
expressors of two commonly used autophagy markers, LC3
(an autophagosome coat protein and a direct marker of
autophagy progression) and p62 (a selective autophagy
chaperone that detects and delivers large biomolecules such as
protein aggregates or organelles to autophagosomes)3. However,
details about the expression of these markers with relation to
plaque progression and their correlation with the observed
autophagy dysfunction remain unknown. Since LC3 levels
correlate with the progression of autophagy and the
accumulation of p62 levels correlate with stalled or
dysfunctional autophagy30, we ﬁrst conducted detailed analysis
of immunostained atherosclerotic plaques from atheroprone
ApoE-null mice and atherosclerotic human carotid samples.
First, we compared the levels and co-localization of LC3 and p62
in aortic root plaques of ApoE-null mice at two stages of
atherogenesis (‘early’ versus ‘advanced’ lesions as deﬁned by the
duration of western diet feeding). LC3 levels were signiﬁcantly
lower in the more advanced lesions, whereas p62 intensity remained
elevated in both early and advanced lesions (Fig. 1a–c). In early
lesions, LC3 levels were still high, and much of the p62 showed
co-localization with LC3; this co-localization markedly waned in
advanced lesions (Fig. 1d,e). Consistent with our previously
reported observation, p62 (a chaperone for polyubiquitinated
protein aggregates) showed high co-localization with polyubiquitin
stains in both lesion types (Supplementary Fig. 1a)6. Overall, these
data indicate that the observed dysfunction in plaque autophagy is
manifested as a constellation of events (that is, p62 accumulation,
decline in LC3/autophagosome formation and an inability to
co-express autophagy markers).
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We were interested in determining whether our ﬁndings in
mouse models are recapitulated in human atherosclerosis and
repeated a similar analysis in human atherosclerotic plaques
obtained from discarded carotid endarterectomy (CEA)
specimens. CEA lesions were dissected immediately postopera-
tively into regions devoid of disease or regions with minimal or
maximal disease, for LC3 and p62 staining. In areas lacking
atherosclerosis, we only detected LC3 without any evidence for
p62 or ubiquitin accumulation by immunoﬂuorescence (IF),
consistent with the presence of basal of autophagy without
aberrant accumulation of autophagic cargo (Supplementary
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diseased regions and increased (that is, p62 staining increased in
both size and number) in maximally diseased regions, although it
did not reach statistical signiﬁcance (Fig. 1f and Supplementary
Fig. 1c). In contrast, the intensity of LC3 staining was
both reduced (Fig. 1f and Supplementary Fig. 1d) and developed
poor localization with p62 (Fig. 1g,h) in maximally diseased
regions. Given the lower co-localization of p62 and LC3, we also
evaluated the staining pattern of p62 and polyubiquitin in the
same samples and found the large majority of p62 co-localized
with polyubiquitin (Fig. 1i,j). Technical limitations precluded
co-staining of plaques with LC3, p62 and polyubiquitin in unison
and direct correlation between all markers. However, comparison
of co-staining correlations between p62 and LC3 and p62 and
polyubiquitin demonstrated signiﬁcantly better correlation for
p62 and polyubiquitin (Fig. 1k). Taken together, these data
suggest that in advancing atherosclerotic plaques the formation
and stagnation of p62-enriched polyubiquitinated aggregates is
favoured over clearance and is a hallmark feature of the
autophagy dysfunction in atherosclerosis.
Macrophage TFEB overexpression rescues plaque autophagy.
The progressive decrease in LC3 levels and p62/LC3 co-localization
as well as the accumulation of polyubiquitinated proteins with
advancing plaque formation led us to investigate methods by which
the autophagic degradation machinery can be stimulated. TFEB is
the predominant transcription factor capable of inducing coordi-
nated expression of autophagy–lysosomal genes and the prode-
gradative response in several cell types including macrophages12–14.
We utilized a previously described tissue-speciﬁc overexpression
model of TFEB in mice and created macrophage-speciﬁc TFEB-
transgenic mice by conducting crosses with mice expressing Cre
under the control of Lysozyme-M promoter (hereafter referred to as
mfTFEB-TG)12,13. Thioglycollate-elicited peritoneal macrophages
(hereafter referred to as macrophages) from these mice showed
increased TFEB expression, more TFEB nuclear localization and
TFEB-induced target gene expression including p62 and LC3
(Fig. 2a–c, Supplementary Figs 2a and 12a). We also found
enhanced autophagic ﬂux in TFEB-TG (tissue-speciﬁc transgenic
expression of TFEB) macrophages by observing baseline elevations
in LC3-I levels with enhanced conversion to LC3-II upon
baﬁlomycin incubation (a lysosomal inhibitor/blocker of
autophagosome degradation; Fig. 2d and Supplementary Fig. 11a).
In addition, p62 levels were persistently higher in agreement with
our gene expression results (Fig. 2c,d). We crossed mfTFEB-TG
mice with green ﬂuorescent protein-tagged LC3 (GFP-LC3)-
expressing mice to be able to further monitor autophagy in
macrophages by live imaging. TFEB-TG macrophages showed
signiﬁcantly more GFP-LC3-positive area in 20min of live imaging,
suggesting induced autophagosome formation even under
unstimulated conditions (Fig. 2e, Supplementary Fig. 2b,c and
Supplementary Movies 1 and2). When these macrophages were
incubated with baﬁlomycin, even higher GFP-LC3 ﬂuorescence was
observed consistent with TFEB-induced increases in autophagic ﬂux
(Fig. 2f, Supplementary Fig. 2d,e and Supplementary Movies 3 and
4). Increased ﬂux was also corroborated by GFP-LC3 dots showing
more co-localization with the lysosome marker Lysotracker in
TFEB-TG macrophages (Fig. 2g, Supplementary Fig. 2f–h and
Supplementary Movies 5 and 6). In agreement with our real-time
live imaging experiments, we observed a signiﬁcantly higher
autophagic ﬂux in TFEB-TG macrophages stained by LC3
immunocytochemistry at both baseline and after 3 h of treatment
with another blocker of lysosomal degradation chloroquine
(Fig. 2h). In keeping with TFEB’s ability to induce the autophagy–
lysosome system as a whole, we also detected increases in LAMP1
expression (a commonly used marker of lysosomes and lysosomal
mass) both in cultured peritoneal macrophages and splenic
macrophages derived from mfTFEB-TG mice (Fig. 2i). In
conclusion, these data suggest that overexpressing TFEB is a
sufﬁcient method to induce the autophagosome formation and
autophagy–lysosomal biogenesis in macrophages.
We next asked whether macrophage-speciﬁc TFEB overexpres-
sion can induce autophagy and autophagy–lysosomal biogenesis in
atherosclerotic plaques in vivo. We crossed mfTFEB-TG mice with
pro-atherogenic ApoE-KO mice and initiated plaque formation by
western diet feeding. TFEB expression as gauged by IF staining of
aortic roots was signiﬁcantly elevated and coincided with plaque
macrophages (Fig. 3a,b). More importantly, TFEB nuclear
localization was particularly elevated in the atherosclerotic plaques
of mfTFEB-TG mice using two independent TFEB-speciﬁc
antibodies (Fig. 3c and Supplementary Fig. 3a). The expression of
both LC3 and p62 was also increased in mfTFEB-TG aortic roots
in agreement with our in vitro macrophage data (Fig. 3d,e).
Interestingly, in direct contrast to what we observed in the
progressive atherosclerosis of mice models and the maximally
diseased regions of human plaques (Fig. 1), mfTFEB-TG
atherosclerotic plaques showed remarkably higher p62-LC3
co-localization and co-staining correlation than control athero-
sclerotic lesions (Fig. 3f,g). Macrophages from mfTFEB-TG
atherosclerotic aortas analysed by ﬂuorescence activated cell sorting
(FACS) analysis also displayed enhanced co-expression of
autophagy and lysosomal markers as gauged by co-staining of
LC3 and p62 as well as LC3 and Lamp2 (Fig. 3h,i). Overall, these
data suggest that macrophage-speciﬁc TFEB overexpression is a
viable approach to induce autophagy and autophagy–lysosomal
biogenesis, reprogramme plaque macrophages to co-associate
autophagy markers and their cargo, and reverse the autophagy
dysfunction observed in advancing atherosclerosis.
Macrophage TFEB overexpression reduces atherosclerosis.
In order to assess the effect of macrophage TFEB overexpression
on plaque progression, we fed cohorts of control and
mfTFEB-TG (on a pro-atherogenic ApoE-null background) a
Figure 1 | Mouse and human atherosclerotic plaques develop features of a progressive autophagy dysfunction. (a–c) Representative
immunoﬂuorescence images of early-stage and more advanced atherosclerotic (ApoE-KO) aortic roots co-stained with antibodies against LC3 and p62.
Early and advanced lesions were obtained from ApoE-KO mice fed a western diet foro2 months and 3–4 months, respectively (scale bar, 50mm (a)). The
mean intensity for LC3 and p62 stainings were analysed (n¼ 5 mice for each group; b,c). (d,e) Co-localization of LC3 and p62 was also analysed in the
same aortic roots. Representative co-localization images are shown from early and more advanced lesions (green indicates LC3/p62 co-localized,
red indicates LC3-positive, and blue indicates p62-positive areas) (d). LC3/p62 co-localization is quantiﬁed as per cent of total signal (e).
(f–k) Immunoﬂuorescence analysis of human carotid endarterectomy specimens (n¼ 8), which are separated as maximally- and adjacent minimally
diseased regions (scale bar, 100mm). Specimens were co-stained with LC3 and p62 (f), and co-localization (g) as well as correlation of staining intensity
(h) between maximally and minimally diseased regions are quantiﬁed. Maximally diseased human atherosclerotic regions were co-stained for p62 and
polyubiquitinated proteins (FK-1 antibody; i), and co-localization quantiﬁed (j). (k) Graph represents a comparison of the staining correlation between
p62/LC3 versus p62/ubiquitin(FK-1) in maximally atherosclerotic regions. For all graphs, data are presented as mean±s.e.m. **Po0.01, ***Po0.001,
two-tailed unpaired t-test. Max, maximum; Min, minimum; Ubiq., ubiquitination.
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Figure 2 | TFEB overexpression induces autophagy and autophagy–lysosomal biogenesis in macrophages. (a–c) Control and TFEB-overexpressing
(TFEB-TG) thioglycollate-elicited peritoneal macrophages (hereafter referred to as macrophages) were assessed as follows: transcript levels of (a) TFEB and
(c) several autophagy–lysosome markers were evaluated by quantitative polymerase chain reaction (qPCR, nZ3 independent wells). (b) TFEB nuclear
localization was assessed by immunoﬂuorescence staining and quantiﬁed as percentage of TFEB-positive nuclei (nZ40 cells per group, scale bar, 20mm).
(d) Western blot analysis of p62 and LC3 in TFEB-TG macrophages after baﬁlomycin (200nM) treatment for indicated times (C, control; T, TFEB-TG).
(e–g) Control and TFEB-TG macrophages also co-expressing GFP-LC3 were evaluated by live imaging (every 30 s for the indicated times) while being
incubated with either (e) DMEM, (f) baﬁlomycin (200nM) or after staining with (g) Lysotracker-red. Graphs represent (e,f) GFP-LC3-positive areas or (g) per
cent of GFP-LC3 co-localized with Lysotracker-red over the indicated times. For e,f each time point is compared with the control GFP-LC3 group (nZ10 cells for
each treatment). (h) LC3 levels and the intracellular pattern were analysed by immunoﬂuorescence staining of baseline (NoTX) or after 3 h of 10mM
chloroquine incubation. Graphs represent the mean LC3 intensity (n¼ 16–46 cells, scale bar, 5mm). (i) FACS analysis of peritoneal and splenic macrophages
from control or macrophage-speciﬁc TFEB-TG mice for LAMP1 expression. For all graphs, three independent experiments were performed; data presented as
mean±s.e.m. *Po0.05, ***Po0.001, two-tailed unpaired t-test. Baf,baﬁlomycin; CHQ, chloroquine; Ctrl, control; DAPI, 4,6-diamidino-2-phenylindole.
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Figure 3 | TFEB overexpression in macrophages induces the autophagy markers LC3 and p62 and restores their co-localization in atherosclerotic
aortic roots. (a,b) Representative immunoﬂuorescence images of atherosclerotic aortic roots (2 months’ western diet) from control and mfTFEB-TG mice
(ApoE-null background) stained with antibodies against TFEB (a), TFEB and MOMA-2 (b; scale bar, 50mm). (c) Quantiﬁcation of the average TFEB
intensity and co-localization with nuclear marker DAPI (n¼4-5 mice per group). (d) Representative immunoﬂuorescence images of atherosclerotic aortic
roots from control and mfTFEB-TG mice stained with p62 and LC3 (scale bar, 50mm). (e) Quantiﬁcation of the p62 and LC3 average intensity from control
and mfTFEB-TG-stained roots (n¼ 13–14 mice per group). (f) Representative pseudocolour image of these p62/LC3 images (green represents co-
localization) and graph depicting the increased p62/LC3 correlation seen in a representative mfTFEB-TG as compared to a control lesion (scale bar,
50mm). (g) Quantiﬁcation of the p62/LC3 co-localization from control and mfTFEB-TG-stained roots shown (n¼ 13–14 mice per group). (h,i) FACS
analysis of aortic macrophages isolated from atherosclerotic aortas of Control or mfTFEB-TG mice (western diet-fed ApoE-KO background, n¼ 3–4 pooled
aortas) and stained for either (h) p62 and LC3, or (i) Lamp2 and LC3 antibodies (per cent of macrophages expressing each marker is shown below plots).
For all graphs, data are presented as mean±s.e.m. *Po0.05, ***Po0.001, two-tailed unpaired t-test.
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Western diet for 8 weeks and quantiﬁed atherosclerotic lesion
formation and parameters of plaque complexity (Fig. 4a details
this study). mfTFEB-TG mice did not show any difference on
serum cholesterol or other common serum metabolites compared
to controls (Fig. 4b and Supplementary Fig. 4a,b). Lesion
quantitation revealed mfTFEB-TG mice were signiﬁcantly
protected from atherosclerosis at both the level of the aortic
root and whole aorta (Fig. 4c,d). Several features of plaque
complexity were also concomitantly reduced: macrophage-
positive and necrotic core areas were slightly reduced but the
apoptotic-positive areas (as assessed by TUNEL staining) and
the combined apoptotic/necrotic-positive areas were markedly
a
Control:   LysM Cre+/–; TFEB-TG –/–; ApoE–/–
mφTFEB-TG:   LysM Cre+/–; TFEB-TG +/–; ApoE–/–
Western diet
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reduced contributing to an approximately 50% reduction in
lesion area (Fig. 4e,f and Supplementary Fig. 4c–e). The
pro-inﬂammatory cytokine interleukin (IL)-1b, which has an
inverse correlation with macrophage autophagy, was also
substantially reduced in the serum of mfTFEB-TG mice
(Fig. 4g). Given the ability of macrophage TFEB to induce
autophagy and autophagy chaperones such as p62, we next
evaluated the functional signiﬁcance of some of these ﬁndings in
cultured macrophages. In a recent detailed study of p62 in
atherosclerosis, we have shown that atherogenic lipids such as
cholesterol crystals render the macrophage autophagy–lysosome
system dysfunctional and lead to accumulation of p62-enriched
polyubiquitinated protein aggregates6. TFEB-TG macrophages
reversed this effect and signiﬁcantly reduced the accumulation of
inclusion bodies (Fig. 4h,i). As we have previously shown, these
inclusions are mostly composed of polyubiquitinated proteins, are
largely devoid of signiﬁcant amounts of lipids (Supplementary
Fig. 4f) and disrupted autophagy of these p62-enriched aggregates
is associated with increased apoptosis and inﬂammasome/IL-1b
activation6. TFEB-TG macrophages also ameliorated these delete-
rious downstream effects by markedly reducing cholesterol
crystal-induced macrophage apoptosis (Fig. 4j) and IL-1b
secretion induced by various inﬂammasome-activating stimuli
(Fig. 4k and Supplementary Fig. 4g). The anti-inﬂammatory
phenotype of TFEB-TG macrophages appeared to be selective
to IL-1b signalling because tumour necrosis factor secretion
was not changed in those macrophages (Supplementary Fig. 4h).
TFEB-TG macrophages also did not appear to show differences
in lipid accumulation or foam cell formation upon challenge
with modiﬁed lipids (Fig. 4l and Supplementary Fig. 4i–k)
despite having a predicted rise in the activity of lysosomal acid
lipase, a known transcriptional target of TFEB (Supplementary
Fig. 4l)12.
TFEB-driven atheroprotection is autophagy and p62 dependent.
Our characterization of mfTFEB-TG mice in vivo and
cultured macrophages in vitro demonstrates TFEB’s ability
to increase macrophage autophagy and autophagy–lysosomal
biogenesis, increase aggrephagy and the clearance of p62-enri-
ched protein aggregates, decrease macrophage apoptosis and the
pro-inﬂammatory cytokine IL-1b, and decrease atherosclerosis
and plaque complexity. In order to determine whether the
TFEB-autophagy-p62-mediated effects are causally linked to the
observed reduction in atherosclerosis, we developed two new lines
of mice by crossing mfTFEB-TG mice with either macrophage-
speciﬁc autophagy-deﬁcient (mfATG5-KO) or p62-deﬁcient
(p62-KO) mice (on a pro-atherogenic ApoE-null background).
Autophagy remained fully inactive in ATG5-KO macrophages
even with concomitant TFEB overexpression as gauged by
absence of the autophagosome marker LC3-II (Supplementary
Figs 5a and 12b).
Consistent with TFEB’s dependence on autophagy, the dual
mfTFEB-TG/ATG5-KO mice were no longer protected from
atherosclerosis (Fig. 5a) with similar serum cholesterol and
other common serum metabolites to controls (Supplementary
Fig. 5b–d). We also observed no differences in parameters
of plaque complexity (Fig. 5b,c). In addition, dual TFEB-TG/
ATG5-KO macrophages subjected to atherogenic lipids were no
longer able to (1) reduce the number of p62-enriched protein
aggregates or (2) blunt the degree of apoptosis (Fig. 5d–f). We
were surprised to ﬁnd out, however, that TFEB retained its ability
to speciﬁcally diminish the inﬂammasome/IL-1b levels even in
the absence of autophagy, suggesting an independent mechanism
that does not appear to be relevant to the mechanism of plaque
reduction (Fig. 5g and Supplementary Fig. 5e,f).
Our ﬁndings with dual mfTFEB-TG/ATG5-KO macrophages
were mirrored with dual mfTFEB-TG/p62-KO mice where again
TFEB’s protective effects on atherosclerosis and lesion complexity
were abrogated in the absence of p62 (Fig. 6a–c and Suppleme-
ntary Fig. 6a–c). As we have described before, the absence of p62
in macrophages leads to a disruption and further accumulation of
polyubiquitinated proteins upon atherogenic lipid treatment6.
TFEB overexpression was unable to reverse this effect, resulting
in a similar degree of polyubiquitinated proteins in dual
TFEB-TG/p62-KO macrophages (Fig. 6d,e). Consistent with the
involvement of cell death pathways, TFEB overexpression was
unable to prevent atherogenic lipid-induced apoptosis (Fig. 6f).
With regard to the inﬂammasome and IL-1b, we were again
surprised to discover that TFEB’s ability to dampen IL-1b
secretion was completely independent of p62 and reafﬁrmed the
notion that TFEB mediates these IL-1b-suppressive effects via
an alternative mechanism that appears to have no physiological
signiﬁcance for atherosclerotic plaque formation (Fig. 6g and
Supplementary Fig. 6d,e).
Trehalose induces macrophage autophagy–lysosomal biogenesis.
In order to leverage the therapeutic beneﬁt of TFEB activation in
macrophages, we were interested in evaluating compounds
capable of stimulating a similar response. The natural
disaccharide trehalose has been reported to have autophagy-
inducing and protein aggregate-reducing effects that parallel
those observed for TFEB, which led us to assess trehalose’s ability
Figure 4 | Macrophage-speciﬁc TFEB overexpression is atheroprotective. (a) Experimental protocol and mouse cohorts used for assessment of
atherosclerosis. (b–g) Control and mfTFEB-TG mice (all on ApoE-KO background) were fed a western diet for 2 months for lesion development. (b) Serum
cholesterol levels at 2 months (nZ14 mice per group). (c) Quantiﬁcation of atherosclerotic plaque burden using Oil Red O-stained aortic root sections with
representative roots shown on right (scale bar, 0.4 mm) and (d) en face analysis of whole aorta (statistical signiﬁcance of differences calculated using
Mann–Whitney U-test). (e) Macrophage content in aortic root sections was analysed by MOMA-2-positive area (nZ12 mice per group). (f) Apoptotic,
necrotic core and combined apoptotic–necrotic core areas of aortic root sections were determined by quantifying TUNEL immunoﬂuorescence staining,
acellular areas or the combined area, respectively (nZ12 mice per group). (g) Serum IL-1b concentration was measured from nZ6 independent samples
derived by pooling serum from two to three mice per sample (412 mice per group). (h) Control and TFEB-TG macrophages treated with or without
cholesterol crystals for 24 h and stained using DAPI (nuclei) and antibodies against polyubiquitinated proteins (FK-1) and p62 (scale bar, 5 mm).
(i) Quantiﬁcation of average p62/ubiquitin-positive dots and average p62 intensity per cell from immunoﬂuorescence experiment described in h
(numbers of cells under each bar). (j) Control and TFEB-TG macrophages were incubated with cholesterol crystals and per cent of caspase 3/7-positive
cells quantiﬁed in three independent experiments. Representative immunoﬂuorescence images are shown on left and numbers of cells shown under each
bar (scale bar, 50mm). (k) Control and TFEB-TG macrophages were treated with LPS (lipopolysaccharide)þ cholesterol crystals (hereafter referred to as
LPSþCC) for 24 h or with LPS followed by ATP for 3 h. Culture media were assayed for IL-1b by ELISA (n¼ 3 independent wells for each treatment).
(l) Control and TFEB-TG macrophages were treated with DiI-acetylated LDL for 12 h and intracellular lipid accumulation quantiﬁed by immunoﬂuorescence
microscopy (nZ187 cell per group, scale bar, 5 mm). For all graphs, data are presented as mean±s.e.m. *Po0.05, **Po0.01, ***Po0.001, two-tailed
unpaired t-test, except c,d.
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to stimulate macrophage autophagy, autophagy–lysosomal
biogenesis and downstream effects on atherosclerosis.
We ﬁrst aimed to determine a therapeutically relevant trehalose
dose that could be tested both in macrophages in vitro and then
in our atherosclerosis mouse models in vivo. This was an
important initial evaluation due to the discrepancy in prior
literature on what constitutes a physiologically effective dose of
trehalose for autophagy induction; many studies use concentra-
tions as high as 100mM in cultured cells that appear to differ
greatly from doses likely achievable in vivo22–28. We thus
administered trehalose to a cohort of mice intraperitoneally
(i.p. 3 g kg 1 body weight), a dose similar to that used in prior
studies involving mouse models22,26,28,29, and determined simple








































































































































































































Figure 5 | Macrophage-speciﬁc TFEB overexpression requires an intact autophagy pathway for atheroprotection including efﬁcient clearance of
polyubiquitinated protein aggregates and reductions in macrophage apoptosis. (a) Cohorts of control and mfTFEB-TG mice (all on mfATG5-KO and
ApoE-KO background) were fed a western diet for 2 months to develop lesions—exact genotypes are provided at the top of the graph. Atherosclerotic
plaque burden was quantiﬁed by computer image analysis of Oil Red O-stained aortic root sections with representative Oil Red O-stained aortic roots
shown on right (scale bar, 0.4mm; statistical signiﬁcance of differences was calculated using Mann–Whitney U-test). (b) Macrophage content in aortic
root sections was analysed by immunoﬂuorescence staining using an antibody against MOMA-2 (nZ10 mice per group). (c) Apoptotic, necrotic core and
combined apoptotic–necrotic core areas of aortic root sections were determined by quantiﬁcation of TUNEL immunoﬂuorescence staining, acellular areas
or a combination of the two, respectively (nZ10 mice per group). (d) Immunoﬂuorescence images of ATG5-KO and ATG5-KO/TFEB-TG macrophages
treated with or without cholesterol crystals for 24 h and stained using DAPI (nuclei) and antibodies against polyubiquitinated proteins (FK-1) and p62
(scale bar, 5 mm). (e) Quantiﬁcation of average p62/ubiquitin-positive dots and average p62 intensity per cell from immunoﬂuorescence experiment
described in d (numbers of quantiﬁed cells are shown under each bar). (f) ATG5-KO and ATG5-KO/TFEB-TG macrophages were incubated with cholesterol
crystals and the per cent of caspase 3/7-positive cells was quantiﬁed in three independent experiments (numbers of quantiﬁed cells are shown under each
bar). (g) ATG5-KO and ATG5-KO/TFEB-TG macrophages were treated with LPSþCC for 24 h or with LPS, followed by ATP for 3 h. Culture media were
assayed for IL-1b by ELISA (n¼ 3 independent wells for each treatment). For all graphs, data are presented as mean±s.e.m. *Po0.05, **Po0.01, NS: not
signiﬁcant, two-tailed unpaired t-test, except a.
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course after bolus injection, trehalose clearly peaks between 30
and 60min (up to a concentration ofB10mM) and then largely
redistributes or is cleared by 2 h (Fig. 7a). We further determined
the kinetics of trehalose in relevant target tissues (aorta, heart and
spleen) by mass spectrometry, and found more sustained tissue
levels with trehalose being detectable for up to 4 h (Fig. 7b).
Trehalose levels in the aorta were also corroborated by a
colorimetric assay (Supplementary Fig. 7a). On the cellular
level, we also found that trehalose is indeed capable of being taken
by macrophages in a concentration-dependent manner (Fig. 7c).
On the basis of this analysis, we chose reasonable doses of
trehalose at 1/10th and 1/100th (that is, 1mM and 100mM) of the
observed peak serum dose to conduct all of our culture analyses.
Using macrophages from GFP-LC3 mice, we ﬁrst conducted
live-cell imaging to quantify autophagosome formation upon short-
term trehalose exposure. Trehalose (1mM but not 100mM) was
able to minimally elevate autophagy within minutes that persisted
at low levels for up to 1 h but was clearly not as potent as nutrient
starvation (PBS) or the autophagosome buildup seen with
































































































































































































Figure 6 | The atheroprotective effect of macrophage-speciﬁc TFEB overexpression is also p62-dependent. (a) Cohorts of control and mfTFEB-TG
mice (all on p62-KO and ApoE-KO background) were fed a western diet for 2 months to develop lesions—exact genotypes are provided at the top of the
graph. Atherosclerotic plaque burden was quantiﬁed by computer image analysis of Oil Red O-stained aortic root sections with representative Oil Red
O-stained aortic roots shown on right (scale bar, 0.4mm; statistical signiﬁcance of differences was calculated using Mann–Whitney U-test).
(b) Macrophage content in aortic root sections was analysed by immunoﬂuorescence staining using an antibody against MOMA-2 (nZ11 mice per group).
(c) Apoptotic, necrotic core and combined apoptotic–necrotic core areas of aortic root sections were determined by quantiﬁcation of TUNEL
immunoﬂuorescence staining, acellular areas or a combination of the two, respectively (nZ11 mice per group). (d) Immunoﬂuorescence images of p62-KO
and p62-KO/TFEB-TG macrophages treated with or without cholesterol crystals for 24 h and stained using DAPI (nuclei), and antibodies against
polyubiquitinated proteins (FK-1) and p62 (scale bar, 5 mm). (e) Quantiﬁcation of average ubiquitin intensity per cell from immunoﬂuorescence experiment
described in d (numbers of quantiﬁed cells are shown under each bar). (f) p62-KO and p62-KO/TFEB-TG macrophages were incubated with cholesterol
crystals and the per cent of caspase 3/7-positive cells was quantiﬁed in three independent experiments (numbers of quantiﬁed cells are shown under each
bar). (g) p62-KO and p62-KO/TFEB-TG macrophages were treated with LPSþCC for 24 h or with LPS followed by ATP for 3 h. Culture media were assayed
for IL-1b by ELISA (n¼ 3 independent wells for each treatment). For all graphs, data are presented as mean±s.e.m. *Po0.05, ***Po0.001,
NS: not signiﬁcant, two-tailed unpaired t-test, except a.
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Fig. 7b–g and Supplementary Movies 7–10). In contrast, macro-
phages treated with trehalose for longer periods (3, 6 and 12h)
displayed more potent autophagy-inducing effects (Fig. 7f and
Supplementary Fig. 7h). The need for longer incubation times
raised the possibility that trehalose’s effects might also relate to
transcriptional activation of autophagy and induction of
autophagy–lysosomal biogenesis. Indeed, beginning at 3 h, treha-
lose signiﬁcantly induced transcripts for a variety of autophagy and
lysosomal genes (Fig. 7g) and concomitantly induced their protein
expression (Fig. 7h and Supplementary Figs 7i and 11b). Moreover,
trehalose was still able to induce some transcriptional activation of
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observed no autophagy induction during the short time course
experiments (Supplementary Fig. 7j), suggesting a more potent role
for trehalose in autophagy–lysosomal biogenesis. In this regard,
we also tested whether relatively short exposure to trehalose
could potentially sustain autophagy for longer durations. Interest-
ingly, macrophages transiently incubated with trehalose for 3 h still
maintained elevations in the autophagy markers LC3 and p62 for
an additional 9 h even in the absence of additional trehalose
exposure (Supplementary Figs 7k and 12c). These sets of experi-
ments suggested that trehalose can promote a sustained autop-
hagy–lysosomal biogenesis programme in macrophages with peak
effect on the order of 6–12h.
Trehalose drives and functionally mimics TFEB activation.
Supporting a role for trehalose in autophagy–lysosomal biogenesis
and TFEB activation, trehalose was able to increase both TFEB
expression at both 1mM and 100mM doses as well as TFEB
nuclear translocation, a surrogate marker for TFEB activation, and
its transcriptional effects (Fig. 8a,b and Supplementary Fig. 11c).
Time course experiments conducted over 24h suggested maximal
trehalose-induced TFEB expression to occur at approximately the
6-h time point coinciding with the transcriptional activation of the
autophagy–lysosomal genes (Supplementary Figs 8a and 12d).
Since TFEB is a member of the MiTF transcription factor family
(which includes MiTF and TFE3) and those transcription factors
have also been previously implicated as inducers of autophagy–
lysosomal biogenesis in different tissues31,32, we also tested the
effects of trehalose on MiTF and TFE3. Interestingly, trehalose had
similar stimulatory effects on TFE3 (as gauged by increased TFE3
transcripts and nuclear translocation) but not MiTF (Fig. 8c–e and
Supplementary Figs 8b–e and 11d).
Because trehalose has the capacity to induce transcriptional
activation of autophagy and autophagy–lysosomal biogenesis in
macrophages, we sought to assess its potential to recapitulate the
functional beneﬁts of macrophage TFEB activation we
had observed in the mfTFEB-TG system. Indeed, trehalose
reduced atherogenic lipid-induced p62-enriched polyubiquiti-
nated protein accumulation as assessed by both immunoblot
and IF (Fig. 8f–i and Supplementary Figs 8f and 11e). Trehalose
also concomitantly blunted macrophage apoptosis and
IL-1b secretion in assays similar to those we conducted for the
TFEB-overexpressing macrophages above (Fig. 8j,k).
Trehalose induces autophagy in vivo and is atheroprotective.
To evaluate whether trehalose has autophagy- and TFEB-indu-
cing properties directly in the plaque, we fed a cohort of GFP-LC3
mice (on a pro-atherogenic ApoE-null background) a western
diet for 6 weeks to develop atherosclerotic lesions followed by an
additional 2 weeks of trehalose administration. A combined
strategy of i.p. (2 g kg 1 body weight, daily) and oral (3% w/v, ad
libitum) trehalose administration was pursued since similar
dosing strategies have been used in prior trehalose studies of
neurodegenerative/protein aggregation disorders22,26,28,29. IF
quantiﬁcation of aortic root atherosclerotic lesions revealed
both increased GFP-LC3 ﬂuorescence (Fig. 9a,b), together with
enhanced TFEB staining and TFEB nuclear localization (Fig. 9c–e
and Supplementary Fig. 9a,b). Splenic macrophages derived from
trehalose-treated mice also showed increased transcripts for a
variety of autophagy and lysosomal genes (Supplementary
Fig. 9c). These data indicate trehalose’s ability to induce
autophagy as well as TFEB activation in vivo in agreement with
our cultured macrophage data and provided the impetus to
conduct a longer-term atherosclerosis study.
A large cohort of pro-atherogenic ApoE-null mice were placed
on a western diet, treated with vehicle, trehalose or sucrose
(a similar non-reducing disaccharide), and atherosclerosis was
quantiﬁed at the level of the aortic root (Fig. 9f, details are this
study). Trehalose administration had no effects on serum
cholesterol levels or other common metabolic parameters
(Fig. 9g and Supplementary Fig. 9d,e). Lesion quantitation
revealed that trehalose-treated mice were signiﬁcantly protected
from atherosclerosis compared to vehicle (Fig. 9h). Furthermore,
the administration of sucrose had no effect and was, in fact,
slightly atherogenic (Fig. 9h). Although the non-reducing nature
of sucrose makes it the ideal control disaccharide in comparison
to trehalose, sucrose is a,b-1,2-linkage of glucose with fructose
rather than trehalose’s a,a-1,1-linkage of glucose with glucose.
Thus, we also administered the reducing disaccharide maltose
(a,a-1,4-linkage of glucose and glucose) to ApoE-null mice in
order to ascertain the uniqueness of trehalose as an atheropro-
tective disaccharide. Maltose administration had no detectable
effect on atherosclerotic plaque burden or on cholesterol levels
(Supplementary Fig. 9f,g).
Finally, our dual i.p. and oral dosing strategy raised the
question of which route of administration contributes most
signiﬁcantly to serum trehalose levels and the observed protection
from atherosclerosis. We were surprised to discover that
i.p. administration of trehalose leads to far greater elevations in
serum trehalose than oral dosing (Fig. 9i). Serum trehalose
levels rose minimally after oral dosing despite the far greater
excess (by weight) provided than i.p. dosing. Thus, to rule-out
off-target effects of oral trehalose in affecting atherosclerotic
lesion formation (for example, effects of trehalose on the
gastrointestinal system or gut microbiota), we conducted an
oral-only trehalose experiment in a cohort of ApoE-null
Figure 7 | Trehalose induces autophagy and the transcription of autophagy–lysosomal genes in macrophages. (a,b) Time course of serum and tissue
trehalose levels from wild-type mice (nZ4) after trehalose administration (3 g kg 1 i.p.) by colorimetric method and mass spectrometry, respectively.
(c) Macrophages were treated with vehicle or trehalose at indicated concentrations for 3 h and intracellular trehalose levels measured by mass
spectrometry (n¼ 2 independent wells). (d) GFP-LC3-expressing macrophages were imaged live every 30 s while being incubated in DMEM
(control)±baﬁlomycin (200nM), PBS (starvation) or trehalose (1mM, 100 mM) for 20min. GFP-LC3-positive area was quantiﬁed (nZ10 cells for each
treatment) and plotted relative to 0min. No signiﬁcant difference seen for DMEM and 100mM trehalose treatments. Trehalose (1mM), baﬁlomycin and
PBS signiﬁcance is demarcated by *, # and z, respectively (Po0.05 for all cases). (e) Protocol as in d but macrophages were imaged live for 1 h (DMEM and
1mM trehalose) or 2 h (100mM trehalose). No signiﬁcant difference seen for DMEM and 100 mM trehalose treatments. *Po0.05 for 1mM trehalose
treatment time points. (f) Wild-type macrophages were incubated with trehalose (1mM; 3 and 6 h), baﬁlomycin (200nM; 6 h) or both (6 h trehalose
pretreatment and 6 h co-incubation) and stained with LC3 antibody and DAPI. Representative images are shown at left and quantiﬁcation of average LC3
intensity with each condition at right (number of cells under each bar). #shows signiﬁcant difference compared to vehicle (using analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test; scale bar, 5 mm). (g) Wild-type macrophages were treated with 1mM trehalose for indicated time
points and transcripts of autophagy–lysosomal genes detected by qPCR (nZ3 independent wells for each gene). (h) Western blot analysis of Cathepsin D,
Lamp1, p62 and LC3 in macrophages after 1mM trehalose treatment for indicated times. Ponceau S staining used as loading control. For graphs
in c,f,g, data are presented as mean±s.e.m. *Po0.05, **Po0.01, ***Po0.001, NS: not signiﬁcant, two-tailed unpaired t-test compared to zero time point
or vehicle, except f.
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mice over 8 weeks of concomitant western diet feeding. Oral
trehalose had no observable effects on either atherosclerosis
or serum cholesterol (Fig. 9j and Supplementary Fig. 9h).
Trehalose reduces atherosclerosis through autophagy and p62.
Similar to mfTFEB-TG mice, the effects of trehalose in vivo and
on cultured macrophages in vitro demonstrate this unique
disaccharide’s ability to increase macrophage autophagy and
autophagy–lysosomal biogenesis, to increase aggrephagy and
the clearance of p62-enrich protein aggregates, to decrease
macrophage apoptosis and the pro-inﬂammatory cytokine IL-1b
and to an overall reduction in atherosclerosis. We set out
to determine whether trehalose’s autophagy-p62-mediated
effects are mechanistically linked to the observed reduction
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and p62-KO mice (both on pro-atherogenic ApoE-null
backgrounds).
Consistent with its speciﬁcity towards macrophage autophagy,
trehalose was no longer able to reduce atherosclerosis in
mfATG5-KO mice (Fig. 10a and Supplementary Fig. 10a–c).
In addition, trehalose was no longer able to reduce the number of
p62-enriched protein aggregates or blunt the degree of apoptosis
when subjected to atherogenic lipids (Fig. 10b,c). Interestingly,
trehalose’s blunting effect on IL-1b secretion was independent of
autophagy, again suggesting an independent mechanism that
appears to have no physiological signiﬁcance for atherosclerotic
plaque formation (Fig. 10d). Finally, abrogation of the ather-
oprotective effects of trehalose, its ability to reduce polyubiqui-
tinated protein aggregates and macrophage apoptosis, and
apparent irrelevance of IL-1b reduction to these phenotypes
were entirely recapitulated in p62-KO mice (Fig. 10e–h and
Supplementary Fig. 10d–f).
Discussion
In this study, we provide both genetic and pharmacological
evidence supporting a protective role for the stimulation of the
macrophage autophagy–lysosomal biogenesis programme in
atherosclerosis. Using the common marker of autophagy
progression (LC3) and the autophagy chaperone (p62), we ﬁrst
show a progressive autophagy dysfunction in the developing
atherosclerotic plaque. We then utilize a macrophage-speciﬁc
TFEB overexpression mouse model to activate the predominant
transcription factor mediating autophagy–lysosomal biogenesis in
macrophages and note its ability to reprogramme plaque
macrophages to co-express LC3 and p62. We show that TFEB
overexpression is able to increase macrophage autophagy both
in vitro and in vivo, and it has functional beneﬁts by increasing
aggrephagy of cytotoxic p62-enriched protein aggregates
concomitant with blunting of lipid-induced macrophage apopto-
sis and IL-1b production. This in turn leads to reduction of
atherosclerotic plaque burden and the development of less
complex lesions with reduced plaque macrophage apoptosis and
necrotic cores. Importantly, using models of autophagy- and
autophagy chaperone deﬁciency (ATG5-KO and p62-KO) we
show the speciﬁcity of macrophage TFEB’s atheroprotective
action. The absence of ATG5 or p62 abrogates TFEB’s ability to
reduce atherosclerosis, plaque complexity, macrophage apoptosis
and aggrephagy of p62-enriched protein aggregates.
In an attempt to leverage the beneﬁcial therapeutic effects of
stimulating macrophage autophagy–lysosomal biogenesis, we
describe the utility of the natural sugar trehalose with previously
described but mechanistically unknown autophagy-inducing
properties. We show that therapeutically relevant doses of
trehalose are able to stimulate macrophage autophagy,
autophagy–lysosomal biogenesis and TFEB both in vitro
and in vivo. Mirroring TFEB action, trehalose increases
aggrephagy of cytotoxic p62-enriched protein aggregates, blunts
lipid-induced macrophage apoptosis and IL-1b production, and
reduces atherosclerotic plaque burden. Similarly, these effects are
abrogated in models of autophagy- and autophagy chaperone
deﬁciency (ATG5-KO and p62-KO). This comprehensive
evaluation of both genetic and pharmacological methods
of enhancing macrophage autophagy–lysosomal biogenesis
demonstrates the utility of this approach in cardiovascular
therapeutics (overview shown in Fig. 10i).
Several unanswered questions remain. First, there is an
ever-expanding list of degradative functions for the autophagy–
lysosomal system spanning both protein and organelle turnover.
In atherosclerosis, the main three proposed mechanisms are
dampened inﬂammasome/IL-1b activation, accelerated removal
of protein aggregates and increased cholesterol efﬂux. We have
focused on two of these mechanisms in the functional evaluation
of the TFEB and trehalose. Our data support a critical role for the
aggrephagy of p62-enriched protein aggregates. We have recently
shown that the formation and autophagic processing of
p62-enriched inclusion bodies is a critical process by which
plaque macrophages mitigate atherosclerotic plaque burden6.
This was evaluated using detailed phenotyping of macrophage
ATG5-, p62- and dual ATG5/p62-deﬁcient mice. Now, we
demonstrate that the autophagy-inducing and atheroprotective
effects of TFEB or trehalose are critically dependent on
aggrephagy, resulting in removal of p62-enriched inclusion
bodies and a reduction in macrophage apoptosis. Surprisingly,
blunted IL-1b release does not appear to be a mechanistic
contributor as the IL-1b-reducing effects of both TFEB and
trehalose are independent of ATG5 or p62. In many
neurodegenerative disorders where protein aggregation is
pathogenic and now most recently in atherosclerotic plaques, it
is evident that corralling insoluble protein aggregates into
p62-enriched inclusions and clearing these inclusions via
autophagy is an important response to prevent cytotoxicity and
apoptosis. However, the exact mechanisms by which insoluble
protein aggregate accumulation can cause apoptosis remain
unknown. Future work delineating the protein and organelle
composition of these p62-enriched inclusion bodies could give
clues to this link.
Although our work implicates the autophagic clearance of
pro-apoptotic and pro-inﬂammatory inclusion bodies as a major
Figure 8 | Trehalose induces TFEB nuclear localization and protects from atherogenic lipid-induced protein aggregation and related sequelae of
apoptosis and inﬂammasome activation. (a) Western blot analysis of TFEB in macrophages after trehalose treatment for indicated times. Ponceau S
staining is shown as loading control and densitometric quantiﬁcation from three separate experiments is shown below. (b) TFEB nuclear localization is
analysed by immunoﬂuorescence staining after trehalose treatment and graphed as nuclear TFEB intensity (nZ40 cells per group, scale bar, 10 mm).
(c) Western blot analysis of other MiTF transcriptional family members (TFE3 and MiTF) after trehalose or chloroquine (CHQ, 10mM) treatments for
indicated doses and times. Ponceau S staining is shown as loading control. (d,e) TFE3 and MiTF nuclear localization was analysed by immunoﬂuorescence
staining after trehalose treatment for indicated times and quantiﬁed by the intensity of nuclear staining (nZ500 cells per group). (f) Western blot analysis
of polyubiquitinated proteins (FK-1 antibody) in detergent-soluble and detergent-insoluble lysate fractions of vehicle (V) or trehalose (T) treated wild-type
macrophages. Lanes 3 and 4 were either vehicle or trehalose pretreated for 3 h, and then co-treatment with cholesterol crystals is performed for 12 h. Lanes
5 and 6 were cholesterol crystal-treated for 6 h and then either treated with vehicle or trehalose alone for another 6 h. (g) Densitometric quantiﬁcation
of f from three similar separate experiments. (h) Immunoﬂuorescence images of wild-type macrophages after indicated treatments using DAPI and
antibodies against polyubiquitinated proteins (FK-1) and p62 (scale bar, 5 mm). (i) Graphs represent average p62/ubiquitinþ dot numbers and average
p62 intensity per cell for immunoﬂuorescence images in h (numbers of quantiﬁed cells are shown under each bar). (j) Wild-type macrophages were
co-incubated with cholesterol crystals and trehalose (or vehicle); the per cent of caspase 3/7-positive cells was quantiﬁed in three independent
experiments (numbers of quantiﬁed cells are shown under each bar). (k) Wild-type macrophages were treated as indicated and cell culture media were
assayed for IL-1b by ELISA (n¼ 3 independent wells for each treatment). For all graphs data are presented as mean±s.e.m. *Po0.05, **Po0.01,
***Po0.001, two-tailed unpaired t-test compared to zero time point or vehicle treatment group.
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Figure 9 | Trehalose administration in mice is atheroprotective. (a,b) GFP-LC3 mice (ApoE-KO background) were fed western diet for 2 months and
administered vehicle or trehalose (2gkg 1 given ﬁve times per week i.p.) in the ﬁnal 2 weeks of diet (n¼4 mice per group). Representative GFP ﬂuorescence
(scale bar, 100mm; a) and quantiﬁcation of GFP intensity in aortic roots by confocal microscopy (n¼4 mice per group; b) is shown. (c–e) TFEB intensity and
nuclear localization in aortic roots of the same cohort used in a was detected by immunoﬂuorescence. Shown are (c) representative aortic root TFEB staining
(scale bar, 100mm), (d) average aortic root TFEB intensity; and (e) TFEB-DAPI co-localization. (f) Diagram summarizing experimental protocol and mice cohorts
used for in vivo assessment of trehalose in atherosclerosis. Mice were fed a western diet for 2 months while being administered either vehicle, trehalose or sucrose
(disaccharides given both i.p. 2 g kg 1 for three times per week and orally 3% ad libitum in drinking water). (g) Serum cholesterol levels at 2 months of western diet
(n¼ 7 mice per group). (h) Quantiﬁcation of atherosclerotic plaque burden by computer image analysis of Oil Red O-stained aortic root sections in the experiment
summarized in f (statistical signiﬁcance of differences was calculated using Mann–Whitney U-test). (i) Serum trehalose levels in wild-type mice (n¼4 per group)
after administration of trehalose (3gkg 1) either by i.p. injection or oral gavage at indicated time points. (j) Quantiﬁcation of atherosclerotic plaque burden by
computer image analysis of Oil Red O-stained aortic root sections in mice fed 2 months of western diet while being administered only oral trehalose (statistical
signiﬁcance of differences was calculated using Mann–Whitney U-test). All data are presented as mean±s.e.m. *Po0.05, two-tailed unpaired t-test except h,j.
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mechanism by which induction of macrophage autophagy–
lysosomal biogenesis ameliorates atherosclerosis, it is important
to consider other contributing factors to the observed plaque
reduction. Both mfTFEB-TG mice and trehalose-treated mice
developed smaller lesions because of a combined decline in
lesion complexity (necrotic core and apoptosis) and macrophage
burden. Factors that mitigate lesional macrophage accumulation
include effects on both ins and outs (that is, monocyte numbers/
inﬁltration versus macrophage clearance via efferocytosis). In the
experiments we performed on thioglycollate-elicited peritoneal
macrophage and splenic macrophages, we did not observe
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monocyte response and tissue inﬁltration is likely normal.
However, given reports linking components of the autophagy
machinery to phagocytosis4,33, it would be interesting to
investigate the additional effects of TFEB, trehalose and
autophagy–lysosome biogenesis on phagocytic processes
generally and efferocytosis in particular.
This is the ﬁrst report demonstrating the use of the natural
sugar trehalose in the treatment of atherosclerosis. We corrobo-
rate previous studies conducted in other disease systems that
trehalose has potent autophagy-inducing properties with an
overall beneﬁcial disease-modifying proﬁle. Compared to many
other trehalose studies, we have gone further by actually
demonstrating the autophagy dependence of trehalose both
in vitro and in vivo. Trehalose’s ability to clear p62-enriched
inclusion bodies in macrophages further shows that trehalose’s
beneﬁcial effects are speciﬁcally dependent on p62 and
aggrephagy. Interestingly, this appears to be mechanistically
similar to prior reports of trehalose in neurodegenerative
disorders (for example, Huntington’s, Parkinson’s and amyo-
trophic lateral sclerosis), which reported its ability to induce the
aggrephagy of neuronal cytoplasmic protein inclusions22,24,26.
Despite the broad ability of trehalose to induce autophagy in
disparate model systems, the precise mechanism by which this
occurs is still unknown. Our interrogation of the timing of this
autophagy induction by live-cell imaging and assessment of the
autophagy–lysosomal biogenesis response suggests that a promi-
nent effect of trehalose action is the stimulation of TFEB and
broad transcriptional activation of autophagy and lysosomal
genes. How is this disaccharide capable of inducing TFEB nuclear
translocation and its transcriptional activation? It is intriguing to
note that trehalose is not inherently cell-permeable and is instead
likely to be taken up by ﬂuid-phase endocytosis34. This would
indicate that trehalose accumulation in the endosome–lysosome
system and modulation of its function is a distinct possibility.
In addition, compared to most disaccharides and particularly
non-reducing disaccharides, trehalose is relatively resistant to acid
hydrolysis favouring its lysosomal retention in an undegraded
form20. Since modulation of lysosome function and pH are potent
triggers for TFEB nuclear translocation (for example, TFEB is
activated by the lysosomotropic acid suppressors chloroquine and
baﬁlomycin)35,36, it would be interesting to further study this
trehalose–lysosome–TFEB dynamic. It should be noted that our
evaluation of the other members of the MiTF/TFE transcription
factor family (namely TFE3 and MiTF) illustrates trehalose’s
ability to also trigger TFE3 but not MiTF nuclear translocation.
As all three family members (in particular TFEB and TFE3) have
been implicated in upregulation of autophagy and lysosome
genes30,31, future work using macrophage-speciﬁc knockout mice
for each and combinations of these transcription factors will be
needed to determine the speciﬁcity of trehalose on macrophage
autophagy–lysosomal biogenesis and effects on atherogenesis.
In addition, systemic administration of an autophagy-inducing
compound could potentially have off-target effects by inciting
cellular degradation in normal tissue, although we are not aware
of overt deleterious effects being noted for trehalose. Hyperactive
autophagy has been a proposed alternative to apoptotic cell death
(that is, autophagy-mediated cell death or most recently termed
autosis)37. Rather, our data suggest that the level of autophagy
and autophagy–lysosomal biogenesis induced by trehalose is
protective against lipid-induced macrophage death in vitro and in
the plaque.
Despite the prospect of a safe and natural sugar as a treatment
for cardiovascular disease, we did not observe protection from
atherosclerosis with oral-only dosing of trehalose. Oral trehalose
resulted in minimal elevations of serum trehalose levels in
contrast to the robust levels seen with intraperitoneal adminis-
tration. The likely reason for this dramatic ﬁrst-pass effect on
ingested trehalose is the presence of mammalian trehalase, the
trehalose-speciﬁc glycosidase present in highest amounts in the
gastrointestinal tract, kidney and liver of all mammals spanning
mice to humans20,38. Thus, future evaluations of trehalose in
animal models and potentially clinical trials of its cardiovascular
efﬁcacy will need to largely consider parenteral formulations or
investigate methods to pharmacologically inhibit trehalase while
administering oral trehalose. This can be directly tested by
determining whether oral trehalose absorption can be augmented
and lead to lower atherosclerosis in trehalase-deﬁcient mice. It is
interesting to note that a recent human genetics study described
single nucleotide polymorphisms in the trehalase gene (TREH),
which resulted in lower levels of trehalase activity and lower
diabetes risk in Pima Indians39. An evaluation of the TREH locus
in large-scale cardiovascular genetics cohorts will also be
insightful.
Methods
Animals. Animal protocols were approved by the Washington University Animal
Studies Committee. All mice used in this study were on C57BL/6 J background
(4N7). Mice with TFEB-TG and ATG5 deﬁciency (ATG5-KO) were as previously
described13,40. These mice were crossed with Cre-recombinase transgenic mice
under the control of the Lysozyme-M promoter to generate macrophage-speciﬁc
ATG5-KO (mfATG5-KO) and TFEB-TG (mfTFEB-TG) mice3,12. p62-KO and
GFP-LC3 mice were as described previously6,41. Crosses between mfTFEB-TG,
mfATG5-KO, p62-KO, GFP-LC3 and ApoE-KO mice generated mice with
mfTFEB-TG, mfATG5-KO, p62-KO, mfTFEB-TG/ATG5-KO, mfTFEB-TG/
p62-KO, mfTFEB-TG/GFP-LC3 or littermate controls on an ApoE-KO
background. TFEB-TG, p62, ATG5, Cre, GFP-LC3 and ApoE genotyping was
performed using standard PCR techniques (Supplementary Table 1)6,13,40–42. Mice
housed in a speciﬁc pathogen-free barrier facility were weaned at 3 weeks of age to
a standard mouse chow, providing 6% calories as fat. For in vivo experiments,
male mice were started on a western-type diet containing 0.15% cholesterol and
Figure 10 | Atheroprotective effects of trehalose are dependent on macrophage autophagy and p62. (a,e) mfATG5-KO (a) or p62-KO mice (e; all on
ApoE-null background) were fed a western diet for 2 months with concurrent vehicle or trehalose administration (2 g kg 1 given three times per week i.p.
and 3% ad libitum in drinking water). Graphs represent quantiﬁcation of Oil Red O-stained atherosclerotic plaques at the level of aortic root (statistical
signiﬁcance of differences was calculated using Mann–Whitney U-test). (b,f) Immunoﬂuorescence images of ATG5-KO (b) or p62-KO (f) macrophages
using DAPI and antibodies against polyubiquitinated proteins (FK-1) and p62 (scale bar, 5 mm). Average p62 intensity (b) or ubiquitin intensity (f) per cell
and number of cells is shown. (c,g) ATG5-KO (c) or p62-KO (g) macrophages were co-incubated with cholesterol crystals and trehalose (or vehicle). Per
cent of caspase 3/7þ cells were quantiﬁed in three independent experiments (number of cells shown under each bar). (d,h) ATG5-KO (d) or p62-KO
(h) macrophages were treated as indicated and cell culture media assayed for IL-1b by ELISA (n¼ 3 independent wells for each treatment). Data are
presented as mean±s.e.m. *Po0.05, NS: not signiﬁcant, two-tailed unpaired t-test except a,e. (i) Graphical summary of the beneﬁts of harnessing
macrophage autophagy–lysosomal biogenesis in atherosclerosis: TFEB overexpression in macrophages initiates its nuclear localization and autophagy–
lysosomal biogenesis (1 and 2). This activation modulates several downstream mechanisms in macrophages that contribute to a reduction in
atherosclerosis (3 and 4), such as decreased IL-1b secretion (3), p62-dependent polyubiquitinated protein sequestration and autophagic clearance and
decreased apoptosis (4). Our data largely implicate the atheroprotective effects of TFEB to be dependent on the aggrephagy of p62-enriched inclusion
bodies and associated reductions in apoptotic cell death (4). The disaccharide trehalose is an inducer of macrophage autophagy and autophagy–lysosomal
biogenesis and reduces atherosclerosis by recapitulating these TFEB-induced pathways (5).
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42% calories as fat (TD 88137, Harlan) at B2 months of age. Unless otherwise
noted, experimental groups that were administered various disaccharides (that is,
trehalose, sucrose or maltose) were injected i.p. (2 g kg 1, three times per week)
while drinking water was supplemented at 3% w/v. For in vitro experiments, both
male and female mice aged between 2 and 6 months were used. In each experiment
only samples from the same sex and similar age were compared.
Human carotid samples. Carotid tissue specimens were obtained from consenting
de-identiﬁed patients from the Institutional Review Board-approved Washington
University School of Medicine Vascular Surgery biobank. The material removed at
the time of CEA was directly placed in cold saline and kept on ice during the
transport to the laboratory. Samples were then rapidly dissected into maximally
diseased atherosclerotic regions and adjacent minimally diseased regions, and
placed in a tissue-freezing medium for sectioning and subsequent immunostaining.
Macrophage culture and treatment. Standard techniques were used to isolate
thioglycollate-elicited peritoneal macrophages43. Brieﬂy, mice were injected with
4% sterile thioglycollate media (Sigma, T9032) i.p., and 4 days later, peritoneal
macrophages were isolated, washed, counted and plated (DMEM with 10% fetal
bovine serum). Following treatments were performed on macrophages: cholesterol
crystals (500mgml 1), chloroquine (10mM; Sigma, C6628), baﬁlomycin
(100 nM; Sigma, B1793), lipopolysaccharide (100 ngml 1; InvivoGen), oxLDL
(50 mgml 1), ATP (5mM; Sigma, A2383) and/or trehalose (100 mM and 1mM;
Sigma, T0167). Treated cells were either harvested at various times for
mRNA or protein isolation using standard techniques or were ﬁxed with
4% paraformaldehyde for IF microscopy. Cholesterol crystals were generated by
subjecting cholesterol powder (Sigma, C8667) to an ethanol precipitation
technique44,45. Cholesterol was dissolved in ethanol (50mgml 1) at 65 C and
crystallized by incubation at  20 C overnight. Crystals were collected by
centrifugation at 3,000 r.p.m., and the remaining ethanol was cleared by subsequent
ddH2O washes. Oxidized low-density lipoprotein (LDL) was generated by
Cu2þ oxidation of LDL (Sigma, L7914)46. LDL (500 mgml 1) was dialysed into
EDTA-free PBS, CuSO4 was added to LDL solution to a ﬁnal concentration of
10mM and the solution was incubated at 37 C for 6 h. Reaction was terminated by
dialysing the LDL solution against 2mM EDTA for 4 h.
FACS analysis. FACS analysis for the assessment of autophagy and lysosomal
markers was performed on cultured macrophages, mouse spleens and aortas.
Macrophages were plated (Greiner 665102), adherent cells were collected with
CellStripper (Corning 25056), ﬁxed in 4% paraformaldehyde and stained with
phycoerythrin-conjugated LAMP1 antibody (BioLegend 121612, 1:200). For
splenic macrophages, spleens were minced, ﬁltered to single-cell suspensions
using a 70mm cell strainer, subjected to red blood cell lysis, and stained with Paciﬁc
Blue-conjugated CD45 (BioLengend 103126, 1:200), ﬂuorescein isothiocyanate-
conjugated F4/80 (BioLengend 123108, 1:200), PerCP-Cy5.5-conjugated CD11b
(BioLengend 101228, 1:200) and phycoerythrin-conjugated LAMP1 (BioLengend
121612, 1:200) antibodies. Aortas (extending from the aortic root to the abdominal
aorta at the level of the renal arteries) were dissected after PBS perfusion, cleaned of
all surrounding tissues, minced and digested for 60min at 37 C in a buffer
consisting of RPMI, 2.5 mgml 1 Liberase (Roche 05401127001), 125mgml 1
DNAse 1 (Sigma D4527) and 0.8mgml 1 hyaluronidase (Sigma H3506). Single-
cell suspensions were collected by passing through a 70-mm cell strainer and then
labelled with ﬂuorochrome-conjugated macrophage markers CD45, F4/80 and
CD11b (as above). For intracellular staining, cells were additionally ﬁxed with
4% paraformaldehyde, permeabilized with 0.3% saponin and were incubated with
p62 (Abcam ab56416, 1:150), LC3 (MBL International PM036, 1:200) and/or
Lamp2 (Abcam ab13524, 1:200) primary antibodies, followed by Alexa Fluor
488- or Alexa Fluor 594-conjugated secondary antibodies (Invitrogen A11005,
A11007 and A11008; all 1:500). All samples were analysed using the BD
Biosciences LSR II ﬂow cytometer and quantiﬁed using FlowJo software.
IF microscopy. IF imaging of macrophages and frozen-tissue sections was
performed using standard techniques47. Brieﬂy, cells or tissues were ﬁxed with
4% paraformaldehyde, blocked, permeabilized (1% BSA, 0.2% milk powder,
0.3% Triton X-100 in TBS; pH 7.4) and incubated with antibodies sequentially. For
all IF imaging analyses of cultured macrophages, at least two mice of each genotype
were used in each experiment and experiments were repeated at least three times.
For all imaging analyses of tissue sections, a representative image was chosen and
shown after analysis of at least four aortic roots or human samples. The number of
analysed cells or tissue sections is indicated in the ﬁgure legends. Speciﬁcity of
staining was tested in control experiments either by omitting primary antibodies or
using samples from knockout mice where available. The following primary
antibodies were used in 1:250 dilutions: p62 (Progen Biotechnik, GP62-C),
polyubiquitinated proteins (FK-1; Enzo Life Sciences, BML-PW8805), MOMA-2
(AbD Serotec, MCA519C), LC3 (MBL, PM036), TFEB (MyBioSource, MBS120432
and Bethyl, A303-673A), MiTF (Thermo Scientiﬁc, MS-771), TFE3 (Sigma Life
Science, HPA023881) and CD68 (Bio-Rad, MCA1957). Species-speciﬁc ﬂuorescent
secondary antibodies were obtained from Invitrogen/Life Technologies (1:250).
CellEvent Caspase 3/7 Green Detection Reagent (Life Technologies, C10423),
DeadEnd Fluorometric TUNEL System (Promega, G3250), LysoTracker-Red
DND-99 (Life Technologies, L7528), DiI-acetylated LDL (Life Technologies,
L3484) and DiI-oxidized LDL (Life Technologies, L34358) were used according to
the manufacturer’s protocol. A Zeiss LSM-700 confocal microscope was used for
imaging. Signal over the threshold was quantiﬁed using ZEN microscope software
(Carl Zeiss Microscopy) after determination of regions of interest and thresholds.
Live-cell imaging. For live imaging, macrophages were plated on glass-bottom
culture dishes (Mattek Corporation, P35G-1.5-10-C). Cells were imaged using a
Nikon A1Rsi Confocal Microscope with Tokai-hit stage-top incubator at 37 C and
5% CO2. Drugs were added after the ﬁrst image, and images was captured every
30 s. Image analysis and quantiﬁcation was performed using ImageJ software.
Regions of interest with thresholds were determined and signal over threshold was
quantiﬁed. Baseline images (image1) were set to unity and other time points were
displayed as changes over this baseline.
Preparation of soluble/insoluble fractions and western blotting. Cells were
lysed in a standard lysis buffer (1% Triton X-100; Cell Signaling, #9803).Where
soluble and insoluble fractions are needed, samples were sonicated and centrifuged
at 17,000g for 15min and supernatant was deﬁned as the soluble fraction. The
pellet (insoluble fraction) was washed with lysis buffer, suspended in boiling
SDS–PAGE loading buffer and sonicated for protein solubilization. Standard
techniques were used for protein quantiﬁcation, separation, transfer and blotting47.
The following primary antibodies were used: TFEB (Bethyl, A303-673A, 1:1,000),
Cathepsin D (gift from Dr Stuart Kornfeld, Washington University, 1:4,000),
Lamp1 (Santa Cruz Biotechnology, sc-19992, 1:2,000), p62/SQSTM1
(abcam, ab56416, 1:2,000), LC3 (Novus Biologicals, NB100-2220, 1:1,000),
polyubiquitinated proteins (FK-2, Millipore, 04-263, 1:1,000), MiTF (Thermo
Scientiﬁc, MS-771, 1:1,000) and TFE3 (Sigma Life Science, HPA023881, 1:1,000).
Analytical procedures and lesion quantiﬁcation. ELISA assays were performed
as per the manufacturer’s protocols to detect secreted IL-1b (R&D Systems,
MLB00B) and tumour necrosis factor-a (BD Biosciences, 560478) from
macrophage culture media. Metabolites (cholesterol, triglycerides and glucose)
were assayed in serum obtained after 6-h fast as per the manufacturer’s protocols
(Thermo Scientiﬁc TR13421, TR22421 and TR15408). For assessment of transcript
levels, quantitative RT–PCR was performed. Oligonucleotide primers were
designed using the qPrimerDepot database http://primerdepot.nci.nih.gov
(Supplementary Table 2). Assays were performed at least in triplicate and
ribosomal protein 36B4 was used for normalization.
For trehalose tolerance test, mice were fasted for 6 h and 3 g kg 1 trehalose was
administered by i.p. or oral gavage. Mice were bled from tail vein at different time
points, blood was centrifuged and serum was analysed by using a trehalose test kit
as per the manufacturer’s protocols (Megazyme, K-TREH).
For aortic root cross-section, hearts were placed in a cryostat mold containing a
tissue-freezing medium and were frozen after the perfusion with PBS. Ten-mm-
thick sections were taken from the samples beginning just caudal to the aortic sinus
and extending into the proximal aorta. Slides were ﬁxed with 4% paraformaldehyde
and stained with Oil Red O. Images were taken with EVOS XL Core Cell Imaging
system, and Oil Red O-positive regions were quantiﬁed using ZEN microscope
software (Carl Zeiss Microscopy). For en face analysis, ﬁxed aorta was incised
longitudinally and pinned ﬂat. Analysed regions included the aortic arch, thoracic
aorta and abdominal aorta (spanning from the aortic valve to the bifurcation of the
iliac arteries)48.
Quantiﬁcation of trehalose levels by mass spectrometry. The GC–MS
(gas chromatography–mass spectrometry) technique was to quantify trehalose
levels in both cells and tissues. The isotope [13C] trehalose (Omicron Biochemicals,
TRE-002) was used as an internal standard during the sample preparation. Samples
were extracted into isopropanol:acetonitrile:water (3:3:2), centrifuged at 18,000g
(15min) and dried under N2 gas. N-Methyl-N-(trimethysilyl) triﬂuoroacetamide
with 10% pyridine in CH3CN was then used to derivatize samples for analysis by
GC–MS using Agilent 7890A gas chromatograph interfaced to Agilent 5975C mass
spectrometer and HP-5ms gas chromatography column (30m per 0.25-mm
internal diameter per 0.25-mm ﬁlm coating). A temperature gradient was used
starting at 80C for 2min, linearly increased at 10C min 1, ending at 300C for
an additional 2min. Samples were subjected to electron ionization mode using
source temperature (200 C), electron energy (70 eV), emission current (300 mA)
and injector/transfer line temperatures (250 C). Monitored ions for trehalose and
[13C] trehalose were m/z 361 and m/z 367, respectively.
Isolation of splenic macrophages. Dissected spleens were minced and single-cell
suspensions prepared by passing the sample through a 70-mm cell strainer. Cells
were washed with 1% BSA in PBS and re-suspended in MACS buffer (0.5% BSA,
2mM EDTA in PBS; 107 splenic cells in 90 ml) followed by addition of 10 ml of
CD11b microbeads (Miltenyi Biotec 130-049-601) for 15min incubation at 4 C.
Cells were washed with MACS buffer, centrifuged at 500g for 10min at 4 C,
re-suspended in 500 ml MACS buffer and transferred to an equilibrated MS
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separation column (Miltenyi Biotec 130-041-301) located in a MACS magnetic
separator (Miltenyi Biotec 130-092-168). The column was washed three times with
MACS buffer and, upon removal of MS column from the magnetic ﬁeld, the bound
CD11bþ fraction was collected with a plunger. After centrifugation (500g for 5min
at 4 C), the cell pellet was used for RNA isolation.
Lysosomal acid lipase activity assay. Lysosomal acid lipase activity was mea-
sured using the ﬂuorogenic substrate 4-methyl-umbelliferyloleate (100mgml 1 in
DMSO). Control or TFEB-TG macrophages were lysed in buffer (10mM Tris pH
8; 50mM NaCl; 1% Triton X-100) containing protease inhibitors and protein
concentrations were measured using the BCA reagent (Pierce, #23225). A mixture
of 4-methyl-umbelliferyloleate substrate, assay buffer (200mM sodium acetate
pH 5.5) and cell lysate (at 1:3:0.2 ratio, 200 ml ﬁnal volume) was incubated for
30min at 37 C and the reaction stopped with 1M Tris pH 8 (100 ml). Fluorescence
intensity was recorded via ﬂuorometric reading (excitation 360 nm/emission
460 nm).
Lipid extraction. Lipids were extracted by using a modiﬁcation of the Folch
method49. Brieﬂy, cells were homogenized in cold 2:1 chloroform:methanol, and
then centrifuged at 12,000 r.p.m. for 10min at 4 C. A 15ml aliquot from the lower
organic phase was isolated and evaporated under nitrogen. Triglyceride content
was assayed as per the manufacturer’s protocols (Thermo Scientiﬁc TR22421).
Statistical analyses. Statistical signiﬁcance of differences was calculated using the
Student’s unpaired t-test or analysis of variance (for multiple groups), followed by
either Dunnett’s test (when multiple groups are compared with a single control) or
Tukey’s multiple comparison test for parametric data or the Mann–Whitney U-test
for non-parametric data (atherosclerosis quantitation). Graphs containing error
bars show the mean±s.e.m. Statistical signiﬁcance is represented as follows:
*Po0.05, **Po0.01, ***Po0.001, NS, not signiﬁcant.
Data availability. All the other data that support the ﬁndings of this study are
available from the corresponding author upon reasonable request.
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